From reprogrammed stem cells to next-generation gene editing, 2024 has seen some incredible developments with the potential to become new treatments.

According to the company, its Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent ...

Aurion Biotech said its cell therapy for treating the cornea improved vision at the highest dose, which it plans to further ...

FECD affects the cornea, at the front of the eye. In FECD, the cells that line the cornea gradually die, causing fluid ...

The team, led by Professor Koji Nishida, used induced pluripotent stem cells (iPS) to perform corneal transplants, marking a significant advancement in treatment. Limbal stem-cell deficiency is a ...

The highest dose of Aurion Biotech’s cell therapy, the main component of which recently received approval in Japan, has ...

A research team led by Professor Hwang Ho-sik of the Catholic University of Korea's Yeouido St. Mary's Eye Hospital has ...

AURN001 is a combination cell therapy product candidate comprised of allogeneic human corneal endothelial cells (neltependocel) and a rho kinase inhibitor (Y-27632). AURN001 is intended to be ...

The corneal transplant market was projected to attain US$ 444.3 million in 2023. It is likely to garner a 5.6% CAGR from 2024 ...